BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 30798508)

  • 1. Targeted therapy of desmoid-type fibromatosis: mechanism, current situation, and future prospects.
    Wang Z; Wu J; Tian X; Hao C
    Front Med; 2019 Aug; 13(4):427-437. PubMed ID: 30798508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Desmoid-type fibromatosis: toward a holistic management.
    Penel N; Kasper B; van Der Graaf WTA
    Curr Opin Oncol; 2021 Jul; 33(4):309-314. PubMed ID: 33973549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current management and recent progress in desmoid tumors.
    Zhou MY; Bui NQ; Charville GW; Ghanouni P; Ganjoo KN
    Cancer Treat Res Commun; 2022; 31():100562. PubMed ID: 35460976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desmoid-type fibromatosis: Current therapeutic strategies and future perspectives.
    Ibrahim R; Assi T; Khoury R; Ngo C; Faron M; Verret B; Lévy A; Honoré C; Hénon C; Le Péchoux C; Bahleda R; Le Cesne A
    Cancer Treat Rev; 2024 Feb; 123():102675. PubMed ID: 38159438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical treatment of mammary desmoid-type fibromatosis: which benefit?
    Scheer L; Lodi M; Molière S; Kurtz JE; Mathelin C
    World J Surg Oncol; 2017 Apr; 15(1):86. PubMed ID: 28420393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Physician's Systemic Treatment Preferences for Patients with Advanced Desmoid-Type Fibromatosis: Experience-Based Medicine in the Absence of High-Level Evidence.
    Schöffski P; Requilé A; van Cann T
    Oncol Res Treat; 2018; 41(4):214-219. PubMed ID: 29562221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Activity and Safety of Anlotinib for Patients with Extremity Desmoid Fibromatosis: A Retrospective Study in a Single Institution.
    Zheng C; Zhou Y; Wang Y; Luo Y; Tu C; Min L
    Drug Des Devel Ther; 2020; 14():3941-3950. PubMed ID: 33061299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of apatinib for patients with advanced extremity desmoid fibromatosis: a retrospective study.
    Zheng C; Fang J; Wang Y; Zhou Y; Tu C; Min L
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):2127-2135. PubMed ID: 33452581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of gamma-secretase inhibitor nirogacestat (PF-03084014) in desmoid tumor: Report of four pediatric/young adult cases.
    Takahashi T; Prensner JR; Robson CD; Janeway KA; Weigel BJ
    Pediatr Blood Cancer; 2020 Oct; 67(10):e28636. PubMed ID: 32762028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor.
    Villalobos VM; Hall F; Jimeno A; Gore L; Kern K; Cesari R; Huang B; Schowinsky JT; Blatchford PJ; Hoffner B; Elias A; Messersmith W
    Ann Surg Oncol; 2018 Mar; 25(3):768-775. PubMed ID: 28887726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of the Gamma Secretase Inhibitor AL101 in Desmoid Tumors: A Case Report of 2 Adult Cases.
    Chan D; Kaplan J; Gordon G; Desai J
    Curr Oncol; 2021 Sep; 28(5):3659-3667. PubMed ID: 34590610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic treatment approaches for sporadic desmoid-type fibromatosis: scarce evidence and recommendations.
    Kasper B
    Oncol Res Treat; 2015; 38(5):244-8. PubMed ID: 25896775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New treatments for desmoid tumors.
    Kasper B
    Curr Opin Oncol; 2023 Jul; 35(4):292-295. PubMed ID: 37222208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Notch signaling pathway in desmoid tumor: Recent advances and the therapeutic prospects.
    Zheng C; Huang J; Xu G; Li W; Weng X; Zhang S
    Biochim Biophys Acta Mol Basis Dis; 2024 Jan; 1870(1):166907. PubMed ID: 37793461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of serious complications in intra-abdominal desmoid-type fibromatosis.
    Bini F; Fiore M; Provenzano S; Bertulli R; Ottini A; Colombo C; Vitellaro M; Greco G; Morosi C; Gronchi A; Casali PG; Palassini E
    Cancer Rep (Hoboken); 2021 Dec; 4(6):e1411. PubMed ID: 34165246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Desmoid-type fibromatosis of the head and neck in children: A changing situation.
    Paul A; Blouin MJ; Minard-Colin V; Galmiche L; Coulomb A; Corradini N; Boutroux H; Van den Abbeele T; Leboulanger N; Denoyelle F; Garabedian EN; Couloigner V; Orbach D
    Int J Pediatr Otorhinolaryngol; 2019 Aug; 123():33-37. PubMed ID: 31059930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG).
    Kasper B; Baumgarten C; Garcia J; Bonvalot S; Haas R; Haller F; Hohenberger P; Penel N; Messiou C; van der Graaf WT; Gronchi A;
    Ann Oncol; 2017 Oct; 28(10):2399-2408. PubMed ID: 28961825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Desmoid Fibromatosis: Management in an Era of Increasing Options.
    Ratan R; Roland CL; Bishop AJ
    Curr Oncol Rep; 2021 Mar; 23(4):41. PubMed ID: 33719012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Desmoid fibromatosis: MRI features of response to systemic therapy.
    Sheth PJ; Del Moral S; Wilky BA; Trent JC; Cohen J; Rosenberg AE; Temple HT; Subhawong TK
    Skeletal Radiol; 2016 Oct; 45(10):1365-73. PubMed ID: 27502790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Desmoid-Type Fibromatosis: Evolving Treatment Standards.
    Fiore M; MacNeill A; Gronchi A; Colombo C
    Surg Oncol Clin N Am; 2016 Oct; 25(4):803-26. PubMed ID: 27591500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.